Inventor
GRIMM JAN
US41 patents
⚠️ This page may combine multiple inventors who share the name “GRIMM JAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NEURIMMUNE HOLDING AG
16 patentsUS10344080B2Jul 9, 2019
Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
NEURIMMUNE HOLDING AG6 citations80
US10961322B2Mar 30, 2021
Human-derived anti-dipeptide repeats (DPRs) antibody
NEURIMMUNE HOLDING AG2 citations72
US10392447B2Aug 27, 2019
Human-derived anti-dipeptide repeats (DPRs) antibody
NEURIMMUNE HOLDING AG2 citations72
US10556946B2Feb 11, 2020
Human derived anti-Huntingtin (HTT) antibodies and uses thereof
NEURIMMUNE HOLDING AG2 citations71
US11180545B2Nov 23, 2021
Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
NEURIMMUNE HOLDING AG3 citations69
US10882902B2Jan 5, 2021
Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof
NEURIMMUNE HOLDING AG1 citations69
US10450365B2Oct 22, 2019
Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
NEURIMMUNE HOLDING AG2 citations68
US10344097B2Jul 9, 2019
Human anti-SOD1 antibodies
NEURIMMUNE HOLDING AG1 citations68
US9771413B2Sep 26, 2017
Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
NEURIMMUNE HOLDING AG2 citations68
US11401325B2Aug 2, 2022
Human-derived anti-huntingtin (HTT) antibodies and uses thereof
NEURIMMUNE HOLDING AG1 citations61
US12234281B2Feb 25, 2025
Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
NEURIMMUNE HOLDING AG0 citations59
US11608372B2Mar 21, 2023
Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
NEURIMMUNE HOLDING AG0 citations58
US11352441B2Jun 7, 2022
Human anti-SOD1 antibodies
NEURIMMUNE HOLDING AG0 citations58
US10072074B2Sep 11, 2018
Human islet amyloid polypeptide (HIAPP) specific antibodies and uses thereof
NEURIMMUNE HOLDING AG1 citations58
US9475866B2Oct 25, 2016
Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof
NEURIMMUNE HOLDING AG1 citations58
US10544213B2Jan 28, 2020
Compounds capable of antagonizing islet amyloid polypeptide (IAPP) induced beta-cell damage and impaired glucose tolerance
NEURIMMUNE HOLDING AG0 citations46
BIOGEN INT NEUROSCIENCE GMBH
8 patentsUS9896504B2Feb 20, 2018
Human anti-alpha-synuclein antibodies
BIOGEN INT NEUROSCIENCE GMBH8 citations83
US9605059B2Mar 28, 2017
Human anti-tau antibodies
BIOGEN INT NEUROSCIENCE GMBH12 citations83
US10259866B2Apr 16, 2019
TDP-43 specific binding molecules
BIOGEN INT NEUROSCIENCE GMBH7 citations81
US9587014B2Mar 7, 2017
TDP-43 specific binding molecules
BIOGEN INT NEUROSCIENCE GMBH7 citations81
US10301381B2May 28, 2019
Anti-alpha synuclein binding molecules
BIOGEN INT NEUROSCIENCE GMBH4 citations71
US9975947B2May 22, 2018
Anti-alpha synuclein binding molecules
BIOGEN INT NEUROSCIENCE GMBH4 citations71
US11091540B2Aug 17, 2021
TDP-43 specific binding molecules
BIOGEN INT NEUROSCIENCE GMBH0 citations59
US10703808B2Jul 7, 2020
Human anti-alpha-synuclein antibodies
BIOGEN INT NEUROSCIENCE GMBH0 citations51
UNIV ZUERICH
3 patentsUS9828420B2Nov 28, 2017
Method of providing disease-specific binding molecules and targets
UNIV ZUERICH14 citations91
US10202445B2Feb 12, 2019
Method of providing disease-specific binding molecules and targets
UNIV ZUERICH7 citations83
US8022268B2Sep 20, 2011
Transgenic animal model for alzheimer's disease
UNIV ZUERICH5 citations54